KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced today the pricing of its $125.0 million aggregate principal amount of 3.250% Convertible Senior Notes due 2031. The notes were issued in a private placement to qualified institutional buyers under Rule 144A of the Securities Act, with a coupon rate of 3.250% and a maturity date of 2031.
Prior to the pricing, the company had announced on September 24, 2025 that it intended to offer $110.0 million of Convertible Senior Notes under the same terms, subject to market conditions. The upsized offering reflects the company’s decision to raise additional capital to support the commercial launch of EKTERLY and ongoing research and development activities.
The new financing provides KalVista with immediate liquidity, extending its cash runway and enabling continued investment in its product portfolio while maintaining the ability to meet commercial and regulatory obligations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.